Affinity Asset Advisors LLC Grows Stock Holdings in Eupraxia Pharmaceuticals Inc. $EPRX

Affinity Asset Advisors LLC grew its stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 429.7% during the 1st quarter, HoldingsChannel reports. The fund owned 1,589,005 shares of the company’s stock after buying an additional 1,289,005 shares during the period. Affinity Asset Advisors LLC’s holdings in Eupraxia Pharmaceuticals were worth $11,504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its holdings in Eupraxia Pharmaceuticals by 44.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 58,058 shares of the company’s stock worth $438,000 after purchasing an additional 17,958 shares in the last quarter. Cibc World Market Inc. grew its holdings in Eupraxia Pharmaceuticals by 287.0% during the 4th quarter. Cibc World Market Inc. now owns 58,050 shares of the company’s stock valued at $437,000 after buying an additional 43,050 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at about $326,000. Bank of America Corp DE increased its position in shares of Eupraxia Pharmaceuticals by 262.9% during the third quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after buying an additional 33,018 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $223,000.

Analysts Set New Price Targets

A number of analysts recently weighed in on EPRX shares. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an “outperform” rating and a $17.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Eupraxia Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $18.00.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ EPRX opened at $5.81 on Friday. The company has a 50-day simple moving average of $6.52 and a two-hundred day simple moving average of $7.35. Eupraxia Pharmaceuticals Inc. has a 12-month low of $5.04 and a 12-month high of $9.32. The firm has a market cap of $377.76 million, a price-to-earnings ratio of -5.53 and a beta of 1.05. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, equities analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.88 EPS for the current year.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.